This is the A1 amended submission of a third competitive renewal of a translational P01 whose continuing goal is to develop and test novel therapies for malignant pleural mesothelioma (MPM) within the structure of a highly interactive multi-disciplinary group that moves from """"""""bench-to-bedside"""""""" and back again. The overall hypothesis is that immuno- and immuno-gene therapy can be used to treat MPM successfully. In the preceding funding period, the Program conducted preclinical work that led to clinical trials using direct intrapleural injection of an adenovirus expressing a type I interferon (Ad.IFN), ultimately leading to a Phase 2 trial, and developed the technology to allow initiation of a clinicl trial using adoptive transfer of genetically modified T-cells that react against the MPM antigen mesothelin. In this proposal, the focus will be on completion of the Phase 2 trial and on moving adoptive T-cell transfer trials forward. The renewal is organized into three projects supported by three Cores. Project 1 (Clinical Trials) will conduct a Phase 2 clinical trial using a combination f intrapleural Ad.IFN and a COX-2 inhibitor with first- or second-line chemotherapy. It will also begin clinical trials using adoptive transfer of gene-modified T-cells. Project 2 (Preclinical Studies) and Project 3 (Genetically Modified T cells) will continue to develop and optimize adoptive immunotherapy for mesothelioma using genetically modified lymphocytes expressing chimeric antigen receptors (CARs). Project 2 will focus on increasing trafficking of T cells into tumors, optimizing combination with chemotherapy, and enhancing T cell function by altering the tumor microenvironment and preventing T cell inactivation. Project 3 will focus on using RNA engineering to create RNA CARs, testing the antitumor activity of combinatorial CAR-based immunotherapy, and conducting experiments using patient material from Project 1 to assess the activity of the transfused T cells. Core A will supply administrative infrastructure. Core B will provide support as the """"""""Tissue Acquisition, Sample Processing, and Pathology Core"""""""". Core C will provide biostatistical and data management services. The goal of this P01 is to alter the treatment paradigm for MPM and advance the entire field of adoptive T cell transfer.

Public Health Relevance

Malignant Pleural Mesothelioma is a highly lethal cancer caused by asbestos exposure. Since current treatments are relatively ineffective, new approaches are needed. This project will to use immuno- and immuno-gene therapy to activate the immune system of the patient or to modify the patient's own lymphocytes to treat this disease. Both animal studies and clinical trials are proposed.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA066726-16
Application #
8477140
Study Section
Special Emphasis Panel (ZCA1-RPRB-B (J1))
Program Officer
Timmer, William C
Project Start
1997-03-01
Project End
2017-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
16
Fiscal Year
2013
Total Cost
$1,111,842
Indirect Cost
$408,128
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Moon, Edmund K; Ranganathan, Raghuveer; Eruslanov, Evgeniy et al. (2016) Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. Clin Cancer Res 22:436-47
Sterman, Daniel H; Alley, Evan; Stevenson, James P et al. (2016) Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy. Clin Cancer Res 22:3791-800
O'Hara, Mark; Stashwick, Caitlin; Haas, Andrew R et al. (2016) Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy. Immunotherapy 8:449-60
Liu, Xiaojun; Ranganathan, Raghuveer; Jiang, Shuguang et al. (2016) A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. Cancer Res 76:1578-90
Liu, X; Barrett, D M; Jiang, S et al. (2016) Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice. Blood Cancer J 6:e430
Newick, Kheng; O'Brien, Shaun; Sun, Jing et al. (2016) Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization. Cancer Immunol Res 4:541-51
Wang, Enxiu; Wang, Liang-Chuan; Tsai, Ching-Yi et al. (2015) Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors. Cancer Immunol Res 3:815-26
Frigault, Matthew J; Lee, Jihyun; Basil, Maria Ciocca et al. (2015) Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res 3:356-67
Lo, Albert; Wang, Liang-Chuan S; Scholler, John et al. (2015) Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. Cancer Res 75:2800-10
Liu, Xiaojun; Jiang, Shuguang; Fang, Chongyun et al. (2015) Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. Cancer Res 75:3596-607

Showing the most recent 10 out of 82 publications